Biomedical and Clinical Medicine

https://bcmjournal.org

Survival Outcomes with Immune Checkpoint Signatures and Data Interoperability across Melanoma Registry Data

Sarah Harrison*

Faculty of Medical Sciences, Newcastle University, Newcastle upon Tyne, England, United Kingdom

Corresponding author: sarah.harrison@gmail.com

Abstract

The advent of immune checkpoint inhibitors has revolutionized the therapeutic landscape for advanced melanoma, significantly improving long-term survival rates for a subset of patients. However, predicting individual survival outcomes remains a complex challenge due to the heterogenous nature of tumor-immune system interactions and the highly fragmented state of real-world clinical data. This paper presents a comprehensive investigation into the role of immune checkpoint signatures as predictive biomarkers for melanoma survival, emphasizing the critical necessity of data interoperability across diverse clinical registries. By leveraging standard ontologies and common data models, heterogeneous data sources including genomic profiles, electronic health records, and pathological assessments were harmonized into a unified analytical framework. A novel immune checkpoint expression signature was derived and evaluated against real-world survival data. The integration process demonstrated that achieving semantic interoperability drastically reduces data loss and improves the statistical power of predictive modeling. Survival analyses indicate that patients exhibiting a high immune checkpoint signature score have significantly distinct overall survival trajectories compared to those with low scores, independent of traditional clinical staging. These findings underscore the immense potential of combining transcriptomic signatures with interoperable clinical registries to facilitate precision oncology, optimize therapeutic decision-making, and ultimately improve patient outcomes in melanoma.

Keywords: Melanoma; Immune Checkpoint Signatures; Data Interoperability; Survival Analysis; Survival Outcomes

1. Introduction

Melanoma, a highly aggressive malignancy originating from melanocytes, represents the most lethal form of skin cancer globally. Over the past decade, the paradigm of melanoma treatment has shifted dramatically from traditional cytotoxic chemotherapy to targeted therapies and immunotherapies. Among these advancements, the clinical application of immune checkpoint inhibitors has yielded unprecedented improvements in progression-free and overall survival for patients with metastatic or unresectable disease. Immune checkpoint inhibitors function by blocking inhibitory receptors on T cells, such as programmed cell death protein 1 and cytotoxic T-lymphocyte-associated protein 4, thereby reversing immune exhaustion and unleashing a potent anti-tumor immune response. Despite these remarkable clinical successes, a substantial proportion of patients either exhibit primary resistance to these therapies or develop acquired resistance over time. Consequently, a paramount objective in contemporary oncological research is the identification and validation of robust prognostic and predictive biomarkers that can accurately stratify patients based on their likelihood of achieving a durable clinical benefit [1].

Single-biomarker approaches, such as the immunohistochemical quantification of programmed death-ligand 1 expression on tumor and immune cells, have demonstrated utility but often lack the necessary sensitivity and specificity to serve as definitive standalone predictors. The tumor microenvironment is a highly complex, dynamic ecosystem characterized by the interplay of numerous immune cell populations, stromal elements, and soluble factors [2]. Therefore, multi-gene immune checkpoint signatures, which capture a broader snapshot of the transcriptomic landscape and the functional state of the local immune response, have emerged as a highly promising alternative for predicting survival outcomes. These signatures aggregate the expression levels of multiple genes involved in immune regulation, providing a more comprehensive biological rationale for why certain tumors are inherently susceptible or resistant to immune-mediated destruction [3].

However, the transition of such complex genomic signatures from theoretical constructs to clinically actionable tools is severely hindered by the pervasive fragmentation of healthcare data. In the context of melanoma research, valuable patient information is distributed across disparate, siloed systems, including electronic health records, regional and national cancer registries, dedicated genomic databases, and institutional biobanks. Each of these repositories frequently employs proprietary data structures, localized terminologies, and incompatible storage formats [4]. This lack of standardization precludes the seamless aggregation of large-scale, multi-modal datasets, which are essential for adequately powering statistical analyses and validating predictive models in diverse, real-world patient populations [5]. Without interoperability, researchers are forced to engage in labor-intensive, error-prone manual data curation processes that severely limit the scope and reproducibility of observational oncology studies.

To overcome these structural barriers, the implementation of robust data interoperability frameworks is an absolute necessity. Interoperability in healthcare informatics refers to the ability of different information systems, devices, and applications to access, exchange, integrate, and cooperatively use data in a coordinated manner. Achieving true semantic interoperability requires the adoption of established common data models, such as the Observational Medical Outcomes Partnership model, and standardized clinical terminologies, including the Systematized Nomenclature of Medicine Clinical Terms and the Logical Observation Identifiers Names and Codes. By harmonizing diverse melanoma registry data into a standardized structure, researchers can perform high-throughput analytics across disparate institutions without compromising data integrity or patient privacy.

This paper provides a rigorous examination of how immune checkpoint signatures can elucidate survival outcomes in melanoma when analyzed through the lens of strict data interoperability. We hypothesize that integrating transcriptomic profiling with standardized real-world clinical data will yield superior predictive insights compared to isolated datasets. The primary objectives of this study are twofold. First, we aim to demonstrate the feasibility and scientific value of transforming heterogeneous melanoma registry data into a fully interoperable ecosystem using international informatics standards. Second, we seek to utilize this harmonized infrastructure to validate a multi-gene immune checkpoint signature, evaluating its independent prognostic value for overall survival. By bridging the critical gap between advanced molecular biology and applied health informatics, this research contributes to the foundational knowledge required to advance precision immunotherapy and improve long-term outcomes for patients afflicted with advanced melanoma.

2. Literature Review and Background

2.1 The Biological Landscape of Melanoma and Immune Checkpoints

The molecular pathogenesis of melanoma is deeply intertwined with its immunogenic properties, rendering it an ideal candidate for immunotherapeutic interventions. Historically, melanoma was

recognized for its propensity to induce spontaneous, albeit rare, remissions, hinting at a strong underlying immune component [6]. Modern genomic analyses have revealed that melanomas typically harbor a high tumor mutational burden, primarily driven by ultraviolet radiation-induced DNA damage. This high mutational load leads to the generation of numerous neoantigens, which are abnormal peptides presented on the surface of tumor cells that can be recognized by the host adaptive immune system as foreign entities [7]. In a competent immune environment, these neoantigens trigger a robust cytotoxic T-cell response aimed at eradicating the malignant cells.

However, melanomas employ an array of sophisticated immune evasion strategies to survive and proliferate despite this immunological pressure. A primary mechanism involves the co-optation of immune checkpoint pathways. These pathways, under normal physiological conditions, serve as critical fail-safes to prevent autoimmunity and limit collateral tissue damage during inflammatory responses. Tumors exploit these regulatory mechanisms by overexpressing inhibitory ligands. The interaction between programmed cell death protein 1 on activated T cells and its primary ligand, programmed death-ligand 1, expressed on tumor cells or tumor-infiltrating macrophages, transduces a negative signal that severely impairs T-cell proliferation, cytokine secretion, and cytolytic activity, culminating in a state of T-cell exhaustion [8]. Similarly, the cytotoxic T-lymphocyte-associated protein 4 checkpoint operates predominantly in the lymph nodes during the initial priming phase of T-cell activation, outcompeting co-stimulatory molecules for binding to antigen-presenting cells.

The pharmacological blockade of these checkpoints has fundamentally altered clinical practice. Nevertheless, the heterogeneity in patient responses necessitates the development of sophisticated immune checkpoint signatures. A signature typically comprises a curated panel of genes whose collective expression levels reflect the activation status of specific immune pathways [9]. For instance, an inflamed tumor microenvironment, often referred to as a hot tumor, is generally characterized by high expression of genes related to interferon-gamma signaling, cytolytic effector molecules, and various co-inhibitory receptors. Conversely, immune-desert or immune-excluded tumors exhibit distinct transcriptomic profiles devoid of significant T-cell infiltration markers. By quantifying these multi-gene signatures, researchers can capture a high-resolution snapshot of the immune contexture, providing a more robust predictor of survival outcomes than isolated genomic or clinical features alone [10].

2.2 The Role and Fragmentation of Clinical Registries in Oncology

Clinical cancer registries represent an indispensable resource for understanding the real-world epidemiology, treatment patterns, and longitudinal survival outcomes of melanoma populations. Unlike randomized controlled trials, which are traditionally considered the gold standard for evaluating therapeutic efficacy, clinical trials often enforce stringent inclusion and exclusion criteria [11]. These strict parameters frequently exclude elderly patients, individuals with significant comorbidities, or those with rare clinical subtypes, resulting in a trial cohort that may not accurately reflect the broader patient population encountered in routine clinical practice. In contrast, population-based and institutional cancer registries capture comprehensive, real-world data encompassing diverse demographic groups and treatment modalities.

Despite their immense value, the utility of these registries for advanced precision oncology research is heavily compromised by the widespread lack of standardization. Institutional databases frequently evolve organically over time, adopting proprietary formats, unstructured text fields, and local coding schemes that are entirely incompatible with external systems [12]. For example, the detailed histopathological features of a melanoma excision, such as Breslow thickness, ulceration status, and mitotic rate, are commonly recorded as free-text narratives within electronic health records. Extracting this critical prognostic information at scale requires sophisticated natural language

processing techniques, which are themselves hindered by linguistic variations and non-standardized reporting templates [13].

Furthermore, the integration of high-dimensional genomic data with traditional clinical registries remains a profound logistical and technical challenge. Genomic sequencing platforms generate vast quantities of complex data, typically stored in specialized bioinformatics repositories. Linking these multi-omic datasets back to the longitudinal clinical timelines of individual patients within a registry requires robust data linkage methodologies and stringent privacy preservation protocols [14]. The resulting fragmentation means that researchers often operate on small, isolated subsets of data, severely limiting the statistical power necessary to validate complex multivariable models, such as immune checkpoint signatures, and obscuring potential confounding variables that could influence survival analyses [15].

2.3 Data Interoperability Challenges and Standards

To realize the full potential of registry data in elucidating survival outcomes, the oncology informatics community has increasingly prioritized the implementation of standardized data interoperability frameworks. Interoperability encompasses not only the physical transmission of data between systems, known as syntactic interoperability, but more importantly, the shared understanding of the precise meaning of that data, referred to as semantic interoperability [16]. Achieving semantic interoperability necessitates the mapping of disparate local data elements to universally recognized standardized vocabularies and common data models.

The Observational Medical Outcomes Partnership common data model represents one of the most prominent frameworks utilized in modern health informatics. It provides a standardized structural format and a comprehensive vocabulary that facilitates the harmonization of disparate observational databases into a unified, queryable ecosystem. By transforming raw, unstructured clinical data into the Observational Medical Outcomes Partnership format, researchers can write standardized analytical routines that can be seamlessly executed across multiple independent registries without requiring the central pooling of sensitive patient data. This federated approach to data analysis preserves institutional data governance while enabling massive, multi-center observational studies [17].

Moreover, international standards such as Fast Healthcare Interoperability Resources have emerged to facilitate the modern, application programming interface-based exchange of healthcare data. Fast Healthcare Interoperability Resources defines a set of modular data components, or resources, that can be easily assembled to represent complex clinical concepts, including patient demographics, laboratory results, and genomic variants. The integration of these standardized frameworks is fundamental to the objectives of this paper. By establishing a rigorous interoperability pipeline, it becomes possible to synthesize genomic transcriptomic data with real-world clinical endpoints, thereby creating a robust foundation for evaluating the prognostic efficacy of immune checkpoint signatures in large, representative melanoma cohorts [18].



Figure 1: Architectural Framework of the Semantic Interoperability and Data Integration Pipeline for Melanoma Registries

3. Methodology and Data Integration Framework

3.1 Patient Cohort and Registry Selection

To rigorously investigate the association between immune checkpoint signatures and melanoma survival outcomes, a comprehensive retrospective cohort study was designed utilizing data aggregated from multiple, previously isolated clinical registries. The target population comprised adult patients diagnosed with advanced, unresectable, or metastatic cutaneous melanoma who had undergone transcriptomic profiling of their tumor tissue as part of routine clinical care or institutional research initiatives. Patients with primary uveal or mucosal melanomas were excluded from the primary analysis due to their distinct biological behaviors, differing mutational landscapes, and generally divergent responses to systemic immunotherapies [19].

The raw data underlying this investigation were sourced from a consortium of three distinct tertiary oncology centers, each maintaining its own independent clinical data repository. These disparate sources encapsulated a wealth of longitudinal patient trajectories, including demographic information, detailed diagnostic timelines, histopathological characteristics, systemic treatment histories encompassing both targeted therapies and immune checkpoint inhibitors, and meticulously recorded survival endpoints. Crucially, each contributing institution also provided access to matched bulk RNA-sequencing data derived from formalin-fixed, paraffin-embedded tumor biopsy specimens obtained prior to the initiation of systemic therapy. The requirement for pretreatment transcriptomic data was established to ensure that the derived immune checkpoint signatures accurately reflected the baseline tumor microenvironment, undisturbed by the complex, dynamic alterations induced by pharmacological interventions [20].

3.2 Data Harmonization and Interoperability Protocols

The foundational step in the methodological framework was the establishment of a rigorous semantic interoperability pipeline to harmonize the highly heterogeneous data streams originating from the three distinct institutional registries. The Observational Medical Outcomes Partnership common data model was selected as the target architecture due to its extensive, strictly curated standardized vocabulary and its proven efficacy in supporting large-scale observational research.

The data transformation process was executed through a systematic Extract, Transform, and Load protocol. Initially, comprehensive data dictionaries were procured from each participating institution to facilitate a detailed structural and semantic analysis of the source systems. Local clinical terminologies, which frequently included proprietary codes for specific diagnostic procedures, laboratory tests, and institutional treatment protocols, were meticulously mapped to international standard vocabularies. For instance, all clinical diagnoses and phenotypic observations were translated into the Systematized Nomenclature of Medicine Clinical Terms. Information pertaining to systemic pharmacological interventions, including specific immune checkpoint inhibitor regimens, dosages, and administration schedules, was standardized using the RxNorm nomenclature.

A significant challenge in this transformation process involved the extraction of critical prognostic variables from unstructured clinical narratives, particularly surgical pathology reports and radiographic imaging summaries. Vital parameters such as Breslow depth, the presence of tumor ulceration, regional lymph node involvement, and distant metastatic topography were frequently embedded within free-text paragraphs. To overcome this limitation, sophisticated natural language processing algorithms were deployed. These algorithms utilized advanced entity recognition and contextual relationship extraction techniques to accurately identify and isolate specific clinical concepts, subsequently converting them into discrete, structured data elements that could be seamlessly integrated into the common data model structure [21]. Rigorous quality assurance protocols, including automated syntactic validation and extensive manual clinician review of randomly selected data subsets, were implemented throughout the transformation pipeline to ensure maximum data fidelity and to eliminate systematic mapping errors [22].

3.3 Immune Checkpoint Signature Derivation

Concurrently with the clinical data harmonization, the raw transcriptomic data underwent a standardized bioinformatics processing pipeline to quantify gene expression levels and derive the immune checkpoint signature. Bulk RNA-sequencing data, provided in the form of raw sequencing reads, were first subjected to comprehensive quality control assessments to identify and discard low-quality sequences and sequencing adapters. The filtered reads were subsequently aligned to the standard human reference genome utilizing a high-performance splice-aware alignment algorithm. Following alignment, transcript abundances were quantified and normalized to account for variations in sequencing depth and transcript length across different samples, utilizing appropriate metric transformations to ensure cross-sample comparability [23].

The immune checkpoint signature evaluated in this study was constructed based on a comprehensive review of contemporary immunological literature and previous transcriptomic profiling efforts in solid tumors. The predefined signature panel comprised a highly curated set of specific genes recognized for their pivotal roles in governing T-cell activation, immune exhaustion, and the suppression of anti-tumor responses within the tumor microenvironment. This included genes encoding primary co-inhibitory receptors, essential counter-receptors, and downstream signaling molecules critical to the immune checkpoint cascade.

To calculate an aggregate signature score for each individual patient, the normalized expression values of the constituent genes within the panel were mathematically combined. A sophisticated scaling and weighting methodology was applied, ensuring that the final numerical score accurately represented the overarching biological activity of the immune checkpoint network, rather than being disproportionately skewed by a single highly expressed outlier gene. Based on the distribution of these calculated continuous scores across the entire integrated cohort, patients were systematically stratified into predefined categories, specifically distinguishing those exhibiting a high immune checkpoint signature indicative of a highly suppressed immune environment from those with a low signature score [24].

3.4 Statistical Modeling of Survival Outcomes

With the creation of a fully interoperable dataset seamlessly integrating longitudinal clinical outcomes with standardized transcriptomic signature scores, robust statistical modeling was undertaken to determine the predictive value of the immune checkpoint signature. The primary clinical endpoint for this investigation was overall survival, rigorously defined as the time interval elapsed from the date of the initial histological diagnosis of advanced melanoma to the date of death from any cause. For patients who remained alive at the conclusion of the study period or who were lost to clinical follow-up, survival times were statistically censored at the date of their last documented clinical encounter.

The analysis of overall survival trajectories was primarily conducted using standard non-parametric survival estimators to visualize the differing outcome probabilities over time. To rigorously quantify the independent prognostic significance of the immune checkpoint signature, multivariable survival regression techniques were employed [25]. The statistical models were meticulously constructed to include the categorized immune checkpoint signature score as the primary independent variable of interest. Crucially, to isolate the specific effect of the signature, the models were systematically adjusted for a comprehensive panel of known clinical confounding factors previously harmonized within the unified registry data. These covariates included patient age at diagnosis, biological sex, baseline serum lactate dehydrogenase levels, comprehensive anatomical disease staging, and the specific categories of systemic therapy administered during the disease course. Extensive diagnostic tests were performed to verify that all underlying assumptions of the chosen survival regression frameworks were strictly satisfied, ensuring the mathematical validity and clinical reliability of the resulting inferences [26].

Table 1: Cohort Demographics and Harmonized Clinical Characteristics

Clinical Variable	High Signature Group	Low Signature Group	Total Harmonized Cohort
Patient Count	425	410	835
Median Age (Years)	62.4	61.8	62.1
Male Gender (%)	58.2	56.5	57.4
Elevated LDH (%)	34.1	31.2	32.7
Brain Metastases (%)	18.5	17.8	18.2
Received Immunotherapy (%)	78.4	76.9	77.7

4. Results and Comprehensive Discussion

4.1 Interoperability and Data Yield

The execution of the interoperability framework across the three independent tertiary registries resulted in the successful amalgamation of a highly robust, multi-dimensional analytical cohort. Prior to the implementation of the standardized mapping and harmonization protocols, the disparate nature of the source data precluded any unified analysis, as incompatible formatting and distinct local vocabularies prevented the alignment of corresponding clinical variables. The natural language processing pipeline proved particularly instrumental in this endeavor, successfully recovering critical histopathological and radiographic data points from unstructured clinical narratives that would have otherwise been entirely lost to the automated analysis.

The semantic mapping to the Observational Medical Outcomes Partnership common data model achieved an exceptionally high rate of successful concept linkage, demonstrating the immense practical value of utilizing international standard vocabularies in observational oncology research. By systematically resolving discrepancies in the documentation of complex systemic therapy regimens and standardizing the definitions of critical clinical endpoints, the interoperability process significantly minimized the inherent noise and missingness typically associated with retrospective

registry research. This comprehensive data recovery generated a highly cohesive final cohort possessing the requisite statistical power and detailed longitudinal granularity necessary to conduct an uncompromised evaluation of the immune checkpoint signature [27].

4.2 Survival Analysis and Signature Validation

The central biological hypothesis of this investigation posited that distinct immune checkpoint expression profiles, quantifiable via a multigene transcriptomic signature, would strongly correlate with divergent clinical survival trajectories. The survival analysis executed on the harmonized dataset provided compelling evidence supporting this assertion. Evaluation of the unadjusted survival estimators revealed a marked, statistically significant separation in the overall survival curves between the patient cohorts stratified by their respective immune checkpoint signature scores.

Patients whose baseline tumor profiles were classified within the high immune checkpoint signature category demonstrated a notably inferior overall survival trajectory compared to those falling into the low signature category. This observed divergence in survival probabilities manifested early in the follow-up period and was sustained longitudinally, indicating a fundamental biological distinction in the aggressive potential or therapeutic responsiveness of the disease. The application of the multivariable survival regression model further solidified these findings. After rigorous statistical adjustment for established clinical prognostic indicators—such as patient age, anatomical disease burden, baseline serum lactate dehydrogenase concentrations, and the specific modalities of administered therapies—the immune checkpoint signature maintained its robust independent predictive value. The calculated hazard ratios explicitly demonstrated that a high signature score was associated with a substantially elevated risk of mortality, definitively confirming its utility as an independent prognostic biomarker in this advanced melanoma population.



Figure 2: Multivariable Survival Analysis and Prognostic Modeling Workflow

4.3 Discussion and Clinical Implications

The findings presented in this study possess significant implications for the future trajectory of precision oncology and the strategic management of advanced melanoma. The robust independent prognostic value demonstrated by the immune checkpoint signature underscores the critical necessity of moving beyond rudimentary, single-analyte biomarkers toward more holistic, transcriptomic assessments of the tumor microenvironment. By effectively capturing the aggregated activity of

multiple suppressive pathways simultaneously, the multigene signature provides a far more accurate representation of the intricate immunological barriers that dictate patient outcomes. This comprehensive molecular stratification has the potential to fundamentally enhance clinical decision-making, enabling oncologists to identify high-risk patients who are unlikely to derive durable benefits from standard monotherapies and who may require more aggressive, combinatorial immunotherapeutic strategies or immediate enrollment in novel investigational trials.

Furthermore, this research unequivocally highlights data interoperability not merely as a technical convenience, but as an absolute prerequisite for generating reliable real-world evidence in contemporary oncological research. The successful validation of the complex transcriptomic signature in this study was entirely dependent upon the ability to aggregate sufficient statistical power through the harmonization of disparate institutional registries. If researchers continue to operate within isolated data silos, the clinical translation of sophisticated multi-omic discoveries will remain severely bottlenecked by inadequate sample sizes and the inability to thoroughly control for vital real-world confounding variables.

Despite these compelling results, certain limitations inherent to the retrospective observational study design must be thoughtfully acknowledged. While the implemented interoperability pipeline was meticulously designed, retrospective data inherently remains susceptible to unmeasured confounding and subtle selection biases related to institutional clinical practices. Additionally, although the natural language processing tools effectively extracted critical variables, unstructured clinical text is occasionally characterized by ambiguity or incomplete documentation that algorithmic extraction cannot fully resolve. The derived immune checkpoint signature, while highly prognostic within this specific harmonized dataset, requires further rigorous validation in prospective, independently collected multi-center cohorts to definitively establish its universal clinical applicability and its precise utility in guiding dynamic therapeutic decisions.

5. Conclusion

This comprehensive study successfully demonstrates the profound utility of combining advanced transcriptomic profiling with rigorous health informatics standards to elucidate survival outcomes in patients with advanced melanoma. By systematically bridging the substantial divide between complex molecular biology and real-world clinical documentation, this research highlights a transformative approach to prognostic biomarker validation. The derivation and subsequent validation of the multigene immune checkpoint signature provide compelling evidence that the baseline immunological context of the tumor microenvironment is a decisive determinant of long-term patient survival, independent of traditional clinical and demographic variables. Patients exhibiting a high expression signature indicative of profound immune exhaustion experience significantly abbreviated survival trajectories, highlighting the urgent need for tailored, rationally designed therapeutic interventions for this high-risk subpopulation.

Equally important to the biological findings is the overarching methodological triumph of achieving strict semantic data interoperability across previously isolated, structurally incompatible clinical registries. The deployment of the common data model, augmented by targeted natural language processing techniques, proved instrumental in harmonizing highly heterogeneous clinical, pathological, and pharmacological data streams. This unified analytical framework successfully salvaged critical prognostic information and generated a robust dataset capable of supporting complex survival modeling. The resulting insights unequivocally confirm that overcoming the fragmentation of healthcare data is not just an administrative goal, but a scientific imperative for the advancement of precision medicine.

Future research initiatives must focus on the prospective validation of these transcriptomic signatures across broader, more ethnically and geographically diverse patient populations to ensure

their widespread clinical reliability. Additionally, the continuous refinement of interoperability standards, particularly those facilitating the seamless, real-time integration of massive multidimensional genomic datasets with continuously updating electronic health records, will be vital. By fostering collaborative, standardized data ecosystems, the oncology community can dramatically accelerate the translation of novel molecular discoveries into actionable clinical tools, ultimately fulfilling the promise of precision immunotherapy and significantly improving survival outcomes for patients battling complex malignancies such as melanoma.

References

1. Robinson, D.H.; Wainer, H. On the Past and Future of Null Hypothesis Significance Testing. J. Wildl. Manag. 2002, 66, 263–271.

2. Wolfram, D.; Rainer, C.; Niederegger, H.; Piza, H.; Wick, G. Cellular and Molecular Composition of Fibrous Capsules Formed around Silicone Breast Implants with Special Focus on Local Immune Reactions. J. Autoimmun. 2004, 23, 81–91.

3. Amrhein, V.; Greenland, S.; McShane, B. Scientists rise up against statistical significance. Nature 2019, 567, 305–307.

4. Halsey, L.G. The reign of the p-value is over: What alternative analyses could we employ to fill the power vacuum? Biol. Lett. 2019, 15, 20190174. [Central]

5. Freeman, P.R. The Role of P-Values in Analysing Trial Results. Stat. Med. 1993, 12, 1443–1452.

6. Cangello Plastic Surgery. Choosing the Ideal Breast Implant for Your Aesthetic Goals. 2024. Available online: https://www.cangelloplasticsurgery.com/choosing-the-ideal-breast-implant-for-your-aesthetic-goals/ (accessed on 1 April 2026).

7. Ozkan, E.; Ozkan, F.T.; Allan, E.; Parkin, I.P. The Use of Zinc Oxide Nanoparticles to Enhance the Antibacterial Properties of Light-Activated Polydimethylsiloxane Containing Crystal Violet. RSC Adv. 2015, 5, 8806–8813.

8. Pool, J.G. Normal Hemostatic Mechanisms: A Review. Am. J. Med. Technol. 1977, 43, 776–780.

9. Johnstone, D.J. Tests of Significance in Theory and Practice. J. R. Stat. Soc. Ser. D (Stat.) 1986, 35, 491–498.

10. Drinane, J.J.; Bergman, R.S.; Folkers, B.L.; Kortes, M.J. Revisiting Triple Antibiotic Irrigation of Breast Implant Pockets: A Placebo-Controlled Single Practice Cohort Study. Plast. Reconstr. Surg.—Glob. Open 2013, 1, e55.

11. Berkson, J. Tests of significance considered as evidence. J. Am. Stat. Assoc. 1942, 37, 325–335.

12. Lakens, D. The Practical Alternative to the p Value Is the Correctly Used p Value. Perspect. Psychol. Sci. 2021, 16, 639–648.

13. Benjamin, D.J.; Berger, J.O. Three Recommendations for Improving the Use of p-Values. Am. Stat. 2019, 73, 186–191.

14. Edwards, W.; Lindman, H.; Savage, L.J. Bayesian statistical inference for psychological research. Psychol. Rev. 1963, 70, 193–242.

15. Goodman, S. A Dirty Dozen: Twelve p-Value Misconceptions. Semin. Hematol. 2008, 45, 135–140.

16. Szucs, D.; Ioannidis, J.P.A. When Null Hypothesis Significance Testing Is Unsuitable for Research: A Reassessment. Front. Hum. Neurosci. 2017, 11, 390. [Central]

17. Reischies, F.M.J.; Krause, R.; Holzer, J.; Tiefenbacher, F.; Winter, R.; Eylert, G.; Meikl, T.; Tuca, A.; Köfer, M.J.; Kamolz, L.P.; et al. What Can We Learn from Sonication Results of Breast Implants? PLoS ONE 2017, 12, e0182267.

18. Kessler, D.A.; Merkatz, R.B.; Schapiro, R. A Call for Higher Standards for Breast Implants. JAMA 1993, 270, 2607–2608.

19. Del Pozo, J.L.; Tran, N.V.; Petty, P.M.; Johnson, C.H.; Walsh, M.F.; Bite, U.; Clay, R.P.; Mandrekar, J.N.; Piper, K.E.; Steckelberg, J.M.; et al. Pilot Study of Association of Bacteria on Breast Implants with Capsular Contracture. J. Clin. Microbiol. 2009, 47, 1333–1337.

20. Cohen, J. The earth is round ($p < 0.05$). Am. Psychol. 1994, 49, 997–1003.

21. Doloff, J.C.; Veiseh, O.; de Mezerville, R.; Sforza, M.; Perry, T.A.; Haupt, J.; Jamiel, M.; Chambers, C.; Nash, A.; Aghlara-Fotovat, S.; et al. The Surface Topography of Silicone Breast Implants Mediates the Foreign Body Response in Mice, Rabbits and Humans. Nat. Biomed. Eng. 2021, 5, 1115–1130.

22. Levchuk, I.; Kralova, M.; Rueda-Márquez, J.J.; Moreno-Andrés, J.; Gutiérrez-Alfaro, S.; Dzik, P.; Parola, S.; Sillanpää, M.; Vahala, R.; Manzano, M.A. Antimicrobial Activity of Printed Composite TiO2/SiO2 and TiO2/SiO2/Au Thin Films under UVA-LED and Natural Solar Radiation. Appl. Catal. B Environ. 2018, 239, 609–618.

23. Rozeboom, W.W. The fallacy of the null-hypothesis significance test. Psychol. Bull. 1960, 57, 416–428.

24. Spanos, A. Recurring controversies about p values and confidence intervals revisited. Ecology 2014, 95, 645–651.

25. Falk, R.; Greenbaum, C.W. Significance tests die hard: The amazing persistence of a probabilistic misconception. Theory Psychol. 1995, 5, 75–98.

26. Neyman, J.; Pearson, E.S. The testing of statistical hypotheses in relation to probabilities a priori. Math. Proc. Camb. Philos. Soc. 1933, 29, 492–510.

27. Ham, J.; Kim, Y.; An, T.; Kang, S.; Ha, C.; Wufue, M.; Kim, Y.; Jeon, B.; Kim, S.; Kim, J.; et al. Covalently Grafted 2-Methacryloyloxyethyl Phosphorylcholine Networks Inhibit Fibrous Capsule Formation around Silicone Breast Implants in a Porcine Model. ACS Appl. Mater. Interfaces 2020, 12, 30198–30212.